GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro
about
sameAs
In vitro characterization of prostanoid FP-, DP-, IP- and TP-receptors on the non-pregnant human myometriumThe mechanism of LTE4-induced histamine hyperresponsiveness in guinea-pig tracheal and human bronchial smooth muscle, in vitroDistinction between relaxations induced via prostanoid EP(4) and IP(1) receptors in pig and rabbit blood vesselsProstanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veinsCharacterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human plateletsEvidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alphaThe identification and characterization of oligodendrocyte thromboxane A2 receptorsThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsProstanoid receptor antagonists: development strategies and therapeutic applicationsInvolvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.The haemodynamic effects of GR 32191, a thromboxane A2 receptor antagonist, in patients with renal artery stenosis and hypertensionPotent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery.Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladderProstanoid receptors involved in the relaxation of human pulmonary vesselsCharacterization of excitatory prostanoid receptors in the human umbilical artery in vitroEffects of some isoprostanes on the human umbilical artery in vitro.Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonistsEP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteriesPiglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes.Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations.Characterization of the prostanoid receptors mediating constriction and relaxation of human isolated uterine arteryGlibenclamide is a competitive antagonist of the thromboxane A2 receptor in dog coronary artery in vitro.Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.Effect of GR32191, a potent thromboxane receptor antagonist, on exercise induced bronchoconstriction in asthma.Thromboxane A2 receptor antagonists.BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting.Sir David Jack: an extraordinary drug discoverer and developer.Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein.Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial arteryProstanoid action on the human pulmonary vascular system.Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model.Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.Interactions between nitric oxide and prostanoids in isolated perfused kidneys of the rat.The role of the epithelium in modulating the responses of guinea-pig trachea induced by bradykinin in vitro.The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjectsPotentiation by endothelin-1 of 5-hydroxytryptamine responses in aortae from streptozotocin-diabetic rats: a role for thromboxane A2Effect of the thromboxane A2-mimetic U46619 on 5-HT1-like and 5-HT2 receptor-mediated contraction of the rabbit isolated femoral artery.
P2860
Q24680324-32FD1A0E-3B20-429B-8DAF-5A68A51CCC9FQ28322346-5ED5A2C8-FB35-4A88-9A6C-97ECBBF4B4A6Q28358198-1B03C257-8B56-49C8-AE53-412061C5D7CFQ28366038-5153A5E5-97FA-4AAE-BC01-540E2852AE55Q28369426-1A9AF6E4-90BE-4DC3-93B9-CFF07506C927Q28378365-1DB41828-1372-4DBD-BC32-D431767C7B3DQ28379254-B399A0C1-27A2-444F-9D4F-3AF2CD7F9EFAQ28577949-0C53EEAB-5CAC-4401-BCB7-B44AC2EF8AD4Q30486707-6D0CEABB-44BB-454D-99C8-D4D4A0A2B861Q33485483-9258454C-538C-4D36-8B76-1282DEEAF10BQ33496841-0567B78C-F351-4D63-A4A6-25173062A397Q34345753-C63B1B42-DCE8-413E-BEBD-B3B60C538A54Q34792425-7080BCBE-BEE3-48D6-ABDB-8278BAF0FC2FQ35027686-5951649B-070C-47D2-9219-044BDF8BD241Q35041074-F5D6351B-072B-4C4B-B07F-15169DFEC8AEQ35041789-CBB87498-9CE9-4364-8055-B5B3593AFE0BQ35041898-5DA717BA-5528-4D71-8092-2946A0296ED4Q35045612-A793499C-ECC4-42EA-8DB1-54794C022C6DQ35046135-BE79DAB9-D0D2-4DA6-B9BC-EDFF138A665CQ35048608-1D262070-1C85-40FC-B6D0-58719E211C26Q35871777-79D7FD13-EC78-4F9F-9E60-EFA896259EBFQ35872742-736D9C0F-B942-4D92-9F8F-C131A13F1A58Q35887899-E6424EB0-EA31-4A1A-B68F-2EC9B1D8EA1EQ35888653-52A13075-2B68-4776-BBD9-0319895B3AEBQ36241117-CDE104A0-4ED5-46B6-A9FB-E75A90521AF3Q37113049-23ACC876-2E28-4916-B3ED-16E0FCE01F70Q37230998-57B8779F-C5C8-41DA-A4D5-C15C983BE9FEQ37929929-839D7CE3-0470-43B8-8E4C-7AD65C20B797Q37953820-CDBF9C16-0577-4047-8D46-5B06552931E6Q40086536-C6ACBE8F-69CA-4050-98DD-30975F1C61C8Q41085331-3EDAF757-0CC0-47C1-BB2F-C71129281379Q41594802-1A4EF0F6-E378-4C6C-87A1-22493CFA1A3DQ41666978-A3EC5A3F-3ECB-4310-BFD0-36A7430F6314Q41834459-3A422046-85C0-4B06-9B92-585A717DF53FQ41834621-EB4E0BEF-2443-4BBE-83AE-FEDD2F8EE3C8Q41940083-F17709EB-87D6-4A83-8067-A5FA4BDC9C27Q42071467-6CCAEF06-E301-4169-A825-3B9087A8B750Q42076448-CD3928AC-8A64-41FA-A3D3-EE97569901FEQ42155826-CC53BE3B-A8BC-4EF7-AC00-B422C4CA884AQ42253035-72A8CD9C-47B3-4389-B21F-CEF430718650
P2860
GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro
description
1989 nî lūn-bûn
@nan
1989 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@ast
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@en
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@nl
type
label
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@ast
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@en
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@nl
prefLabel
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@ast
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@en
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@nl
P2093
P2860
P1476
GR32191, a highly potent and s ...... airways smooth muscle in vitro
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1989.TB12017.X
P407
P577
1989-07-01T00:00:00Z